文献速递神经创伤神经重症

使用阿司匹林与P2Y12反应测定检测创伤性脑损伤抗血小板治疗患者血小板输注后血小板抑制的逆转

Use of Aspirin and P2Y12 Response Assays in Detecting Reversal of Platelet Inhibition With Platelet Transfusion in Patients With Traumatic Brain Injury on Antiplatelet Therapy.
PubMed 文献 · Neurosurgery · 2017-01-01

该前瞻性比较队列研究纳入2010至2015年间头部CT阳性且有抗血小板治疗史的患者107例,于入院时和输注后6小时行ARU与PRU测定,主要终点为检测血小板输注后去抑制。结果显示,服用阿司匹林者中7%、服用氯吡格雷者中27%入院时未达治疗水平;输注后,服用任何阿司匹林者51%、服用任何氯吡格雷者67%未能逆转。

要点

  • 服用阿司匹林者7%、服用氯吡格雷者27%入院时未达治疗水平,可能不会从血小板输注中获益。
  • 血小板输注后,服用任何阿司匹林者51%、服用任何氯吡格雷者67%未能逆转血小板抑制。
  • 服用任何阿司匹林者每单位单采血小板ARU增加71±76,服用任何氯吡格雷者每单位单采血小板PRU增加48±46。

核心结论

  • 相当比例服用阿司匹林或氯吡格雷的患者未达治疗水平,因此不太可能从血小板输注中获益。
  • 在存在可测血小板抑制的患者中,单次血小板输注不足以逆转近一半患者的血小板抑制。

研究设计与样本

  • 2010至2015年间开展的前瞻性比较队列研究,纳入头部CT阳性且有抗血小板治疗史的患者。
  • 入院时及输注后6小时行ARU和PRU测定,主要终点为检测血小板输注后去抑制。
  • 107例患者可进行分析。

主要发现

  • 服用阿司匹林者7%入院时按ARU未达治疗水平,服用氯吡格雷者27%按PRU未达治疗水平。
  • 血小板输注后,服用任何阿司匹林者51%未能逆转,服用任何氯吡格雷者67%未能逆转。
  • 服用任何阿司匹林者每单位单采血小板ARU增加71±76,服用任何氯吡格雷者每单位单采血小板PRU增加48±46。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: At present, guidelines are lacking on platelet transfusion in patients with a traumatic intracranial bleed and history of antiplatelet therapy. The aspirin and P2Y 12 response unit (ARU and PRU, respectively) assays detect the effect of aspirin and P2Y 12 inhibitors in the cardiac population. OBJECTIVE: To describe the reversal of platelet inhibition after platelet transfusion using the ARU and PRU assays in patients with traumatic brain injury. METHODS: Between 2010 and 2015, we conducted a prospective comparative cohort study of patients presenting with a positive head computed tomography and a history of antiplatelet therapy. ARU and PRU assays were performed on admission and 6 hours after transfusion, with a primary end point of detection of disinhibition after platelet transfusion. RESULTS: One hundred seven patients were available for analysis. Seven percent of patients taking aspirin and 27% of patients taking clopidogrel were not therapeutic on admission per the ARU and PRU, respectively. After platelet transfusion, 51% of patients on any aspirin and 67% of patients on any clopidogrel failed to be reversed. ARU increased by 71 ± 76 per unit of apheresis platelets for patients taking any aspirin, and PRU increased by 48 ± 46 per unit of apheresis platelets for patients taking any clopidogrel. CONCLUSION: A significant percentage of patients taking aspirin or clopidogrel were not therapeutic and thus would be unlikely to benefit from a platelet transfusion. In patients with measured platelet inhibition, a single platelet transfusion was not sufficient to reverse platelet inhibition in almost half.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Choi PA, Parry PV, Bauer JS, et al. Use of Aspirin and P2Y12 Response Assays in Detecting Reversal of Platelet Inhibition With Platelet Transfusion in Patients With Traumatic Brain Injury on Antiplatelet Therapy. Neurosurgery. 2017. PMID: 28362883. doi:10.1227/NEU.0000000000001401

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。